Clinical trial
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG…
NCT00490139 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00490139 |
|---|---|
| Title | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D |
| Official title | A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer |
| Acronym | ALTTO |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | North Central Cancer Treatment Group National Cancer Institute (NCI) NIH Breast International Group Canadian Cancer Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Biological, Drug |
| Interventions | Lapatinib, Trastuzumab |
| Enrollment | 8,381 |
| Start date | May 16, 2007 |
| Primary completion | Dec 6, 2013 |
| Completion | Jul 1, 2021 |
| First posted | Jun 22, 2007 |
| Last update posted | Mar 21, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Estonia and 32 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: